Biontech Se ADR (BNTX)

$116.57 +5.68 (5.12%)
Market Cap 29.48B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.02
Volume 2,960,700
Avg Vol 1,176,274
Day's Range N/A - N/A
Shares Out 252.88M
Stochastic %K 87%
Beta 1.27
Analysts Strong Sell
Price Target $123.67

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
TamaraBentley330
TamaraBentley330 Aug. 24 at 10:04 AM
$MA $PG $NEM $BNTX $GFS Mastercard benefits from global payment volumes, Procter & Gamble benefits from resilient consumer-staples demand, Newmont benefits from gold prices, BioNTech advances oncology and vaccine programs, and GlobalFoundries benefits from semiconductor foundry demand. I'm watching transaction growth, consumer spending, gold prices, clinical catalysts, and foundry utilization.
0 · Reply
DennisRussell675
DennisRussell675 Aug. 24 at 9:43 AM
$BNTX $LPLA $EIX $PBA $NMR BioNTech remains focused on oncology and vaccine development, LPL Financial benefits from advisor and asset growth, Edison International provides regulated utility exposure, Pembina Pipeline benefits from Canadian energy infrastructure, and NMR remains execution-dependent. I'm watching clinical milestones, market levels, power demand, energy volumes, and liquidity.
0 · Reply
mollielatham
mollielatham Aug. 24 at 1:55 AM
$BNTX should b 200 + with the cash they have and many more drugs in cancer development
0 · Reply
Hunchinvestor
Hunchinvestor Aug. 24 at 12:07 AM
$BNTX Almost 120 premarket!!
0 · Reply
topstockalerts
topstockalerts Aug. 22 at 1:20 AM
$BNTX the market is treating this stock very differently today.
0 · Reply
pont9
pont9 Aug. 22 at 12:36 AM
$BNTX $IBRX $SMMT $IOVA Anyone else here going to the ESMO congress in October? I'm wondering if there's a way to get a exhibition badge without having to pay the ridiculous pricetag. Let me know..
3 · Reply
StocktwitsNews
StocktwitsNews Aug. 22 at 12:19 AM
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ $ARCT $MRNA $MRK $BNTX $XBI https://stocktwits.com/news/equity/markets/arct-surges-over-60-toward-best-week-in-year-as-moderna-cancer-win-lifts-sector-retail-says-arcturus-getting-harder-to-dismiss/cZYfk0XRJVh
0 · Reply
moneybag888
moneybag888 Aug. 21 at 9:25 PM
$REGN #befirst #believe $BNTX $PFE $MRNA $MRK
0 · Reply
rpc630
rpc630 Aug. 21 at 6:01 PM
$SLS $MRNA $MRK $BNTX This is one heck of a dirt bag. 🚫 !!!
0 · Reply
Juicy_John
Juicy_John Aug. 21 at 5:59 PM
$SLS $MRNA $MRK $BNTX cancer vaccine pump and dumps on these biotechs, get ready to short them! They had the whole world fooled during COVID as they pumped their covid vaccine biotech stocks, this time it will not be that easy to fool people with a cancer vaccine pump, people won’t fall for the same trick twice a lot of bagholders including institutions are looking for any significant pop to sell and many insiders loaded the bottom, just wait until the rug pull comes and this dumps hard again, fool me once shame on you fool me twice shame on me!
4 · Reply
Latest News on BNTX
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Aug 20, 2026, 5:30 AM EDT - 4 days ago

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

BioNTech rises 20.3%

2026-08-19T16:05:37.000Z - 5 days ago

BioNTech rises 20.3%

BioNTech rises 21.6%

2026-08-19T14:00:12.000Z - 5 days ago

BioNTech rises 21.6%

BioNTech price target lowered to $130 from $135 at Evercore ISI

2026-08-05T14:23:35.000Z - 19 days ago

BioNTech price target lowered to $130 from $135 at Evercore ISI

BioNTech price target raised to $142 from $138 at Canaccord

2026-08-05T11:05:37.000Z - 19 days ago

BioNTech price target raised to $142 from $138 at Canaccord

BioNTech price target lowered to $125 from $130 at Citi

2026-08-05T10:35:32.000Z - 19 days ago

BioNTech price target lowered to $125 from $130 at Citi

BioNTech SE Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 20 days ago

BioNTech SE Earnings Call Transcript: Q2 2026

BioNTech SE Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 20 days ago

BioNTech SE Earnings release: Q2 2026

BioNTech SE Slides: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 20 days ago

BioNTech SE Slides: Q2 2026

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

Aug 4, 2026, 7:12 AM EDT - 20 days ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

PFE

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

Aug 4, 2026, 7:02 AM EDT - 20 days ago

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

BioNTech cuts FY26 revenue view to EUR 1.6B-EUR 1.9B from EUR 2B-EUR 2.3B

2026-08-04T10:50:25.000Z - 20 days ago

BioNTech cuts FY26 revenue view to EUR 1.6B-EUR 1.9B from EUR 2B-EUR 2.3B

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

Aug 4, 2026, 6:45 AM EDT - 20 days ago

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BioNTech says Sobi's Oelkers will replace Sahin as CEO

Aug 3, 2026, 5:29 AM EDT - 21 days ago

BioNTech says Sobi's Oelkers will replace Sahin as CEO

BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed

2026-08-03T09:05:08.000Z - 21 days ago

BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

Aug 3, 2026, 5:00 AM EDT - 21 days ago

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU

2026-07-29T20:42:19.000Z - 25 days ago

EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU

PFE

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Jul 29, 2026, 4:30 PM EDT - 25 days ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

PFE

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

Jul 21, 2026, 6:45 AM EDT - 4 weeks ago

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

BioNTech price target lowered to $119 from $126 at Morgan Stanley

2026-07-08T11:40:53.000Z - 6 weeks ago

BioNTech price target lowered to $119 from $126 at Morgan Stanley

BioNTech held buyer talks over four German sites set to close, Handelsblatt reports

Jul 3, 2026, 1:51 AM EDT - 7 weeks ago

BioNTech held buyer talks over four German sites set to close, Handelsblatt reports

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Jun 17, 2026, 2:38 AM EDT - 2 months ago

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

MRNA

BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial

2026-05-31T21:45:07.000Z - 3 months ago

BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial

BMY

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

May 30, 2026, 2:15 PM EDT - 3 months ago

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

This Biotech's Cancer Portfolio Could End Its Rough Patch

May 27, 2026, 11:07 AM EDT - 3 months ago

This Biotech's Cancer Portfolio Could End Its Rough Patch

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

May 22, 2026, 5:00 AM EDT - 3 months ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026, 4:15 PM EDT - 3 months ago

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech SE Transcript: AGM 2026

May 15, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Transcript: AGM 2026

BioNTech Announces New ADS Repurchase Program

May 7, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces New ADS Repurchase Program

Germany says vaccine supply secure despite BioNTech production loss

May 6, 2026, 7:44 AM EDT - 3 months ago

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings Call Transcript: Q1 2026

BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings release: Q1 2026

BioNTech SE Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Slides: Q1 2026

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

May 5, 2026, 7:26 AM EDT - 3 months ago

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

May 5, 2026, 6:47 AM EDT - 3 months ago

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

May 5, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Two experimental drugs showed striking early results against pancreatic cancer

Apr 21, 2026, 5:35 PM EDT - 4 months ago

Two experimental drugs showed striking early results against pancreatic cancer

RVMD

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

Apr 21, 2026, 6:45 AM EDT - 4 months ago

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Apr 11, 2026, 7:00 AM EDT - 4 months ago

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 5 months ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 24, 2026, 6:45 AM EDT - 5 months ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 2:48 PM EDT - 5 months ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 1:29 PM EDT - 5 months ago

One simple reason why BioNTech stock is a raging buy on today's crash

BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings Call Transcript: Q4 2025

BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Annual report: Q4 2025

BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings release: Q4 2025

BioNTech SE Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Slides: Q4 2025

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 5 months ago

Scientists behind COVID-19 vaccine will depart BioNTech

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 7:18 AM EDT - 5 months ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 5 months ago

BioNTech Cofounders to Leave to Form New Company

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:49 AM EDT - 5 months ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:45 AM EDT - 5 months ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Mar 10, 2026, 6:33 AM EDT - 5 months ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 24, 2026, 6:45 AM EST - 6 months ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 6 months ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 28, 2026, 8:00 AM EST - 7 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 7 months ago

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 7 months ago

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 8 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Jan 9, 2026, 10:00 AM EST - 8 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 8 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 9 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 9 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 9 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 9 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 9 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 9 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 10 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 10 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Transcript: R&D Day

BioNTech SE Slides: R&D Day

Nov 11, 2025, 9:00 AM EST - 10 months ago

BioNTech SE Slides: R&D Day

BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings Call Transcript: Q3 2025

BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Earnings release: Q3 2025

BioNTech SE Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 10 months ago

BioNTech SE Slides: Q3 2025

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 10 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 10 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 10 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 10 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

TamaraBentley330
TamaraBentley330 Aug. 24 at 10:04 AM
$MA $PG $NEM $BNTX $GFS Mastercard benefits from global payment volumes, Procter & Gamble benefits from resilient consumer-staples demand, Newmont benefits from gold prices, BioNTech advances oncology and vaccine programs, and GlobalFoundries benefits from semiconductor foundry demand. I'm watching transaction growth, consumer spending, gold prices, clinical catalysts, and foundry utilization.
0 · Reply
DennisRussell675
DennisRussell675 Aug. 24 at 9:43 AM
$BNTX $LPLA $EIX $PBA $NMR BioNTech remains focused on oncology and vaccine development, LPL Financial benefits from advisor and asset growth, Edison International provides regulated utility exposure, Pembina Pipeline benefits from Canadian energy infrastructure, and NMR remains execution-dependent. I'm watching clinical milestones, market levels, power demand, energy volumes, and liquidity.
0 · Reply
mollielatham
mollielatham Aug. 24 at 1:55 AM
$BNTX should b 200 + with the cash they have and many more drugs in cancer development
0 · Reply
Hunchinvestor
Hunchinvestor Aug. 24 at 12:07 AM
$BNTX Almost 120 premarket!!
0 · Reply
topstockalerts
topstockalerts Aug. 22 at 1:20 AM
$BNTX the market is treating this stock very differently today.
0 · Reply
pont9
pont9 Aug. 22 at 12:36 AM
$BNTX $IBRX $SMMT $IOVA Anyone else here going to the ESMO congress in October? I'm wondering if there's a way to get a exhibition badge without having to pay the ridiculous pricetag. Let me know..
3 · Reply
StocktwitsNews
StocktwitsNews Aug. 22 at 12:19 AM
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ $ARCT $MRNA $MRK $BNTX $XBI https://stocktwits.com/news/equity/markets/arct-surges-over-60-toward-best-week-in-year-as-moderna-cancer-win-lifts-sector-retail-says-arcturus-getting-harder-to-dismiss/cZYfk0XRJVh
0 · Reply
moneybag888
moneybag888 Aug. 21 at 9:25 PM
$REGN #befirst #believe $BNTX $PFE $MRNA $MRK
0 · Reply
rpc630
rpc630 Aug. 21 at 6:01 PM
$SLS $MRNA $MRK $BNTX This is one heck of a dirt bag. 🚫 !!!
0 · Reply
Juicy_John
Juicy_John Aug. 21 at 5:59 PM
$SLS $MRNA $MRK $BNTX cancer vaccine pump and dumps on these biotechs, get ready to short them! They had the whole world fooled during COVID as they pumped their covid vaccine biotech stocks, this time it will not be that easy to fool people with a cancer vaccine pump, people won’t fall for the same trick twice a lot of bagholders including institutions are looking for any significant pop to sell and many insiders loaded the bottom, just wait until the rug pull comes and this dumps hard again, fool me once shame on you fool me twice shame on me!
4 · Reply
Dermvesting
Dermvesting Aug. 21 at 3:07 PM
$BNTX Strong pipeline advancing in studies. Bright future
0 · Reply
anon75634
anon75634 Aug. 21 at 2:57 PM
$BNTX People wont realize it, yet. But this week was the real start for mrna cancer vaccines. Something most experts didn't think is possible. This is not like covid - this will stay. And Biontech is a extremly cheap buy to ride that wave.
0 · Reply
eightytwentie
eightytwentie Aug. 21 at 2:52 PM
$BNTX market is highly inefficient Biontech has a larger more mature pipeline than Moderna and way more cash Expect BioNTech to move to $400-500 quickly in 6 months 5 years from now with a mature proven revenue generating pipeline it should be $2,000
0 · Reply
anon75634
anon75634 Aug. 21 at 2:43 PM
$BNTX If you look at $MRNA market cap gain after the positive P3 data the market values this first mrna cancer drug at 40 bln USD for Moderna. And this is after splitting the profits mit Merck. If you assume the same approach by BioNTech leads to comparable results this could equal a 80 bln in market cap gain just for iNest. The best part: iNest is not the only P3 cancer drug by Biontech. It is one of 20+ P3 studies. Smart money will gather here and wait for the events to come. The approach is validate and the upside is huge. And we don't share the profits with anyone.
0 · Reply
htw7448
htw7448 Aug. 21 at 2:37 PM
$BNTX finally :)
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 21 at 2:21 PM
$BNTX MRNA's MC is now almost $54B while BNTX's is only $28B. MRNA is worth double that of BNTX? No way in hell. BNTX is equally valuable or even more valuable than MRNA for sure. Just ride this for life long wealth. JMO
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Aug. 21 at 2:19 PM
$BNTX
0 · Reply
omaia
omaia Aug. 21 at 2:03 PM
$BNTX https://x.com/JooMaia60253128/status/2090801966670598169
0 · Reply
Pillemann1
Pillemann1 Aug. 21 at 2:03 PM
$BNTX is it still Moderna related?
0 · Reply
Quantumup
Quantumup Aug. 21 at 12:19 PM
Stifel reiterated $INBX Buy-$325 after it recently hosted a series of investor meetings w/ Mark Lappe (Founder, CEO) & Kelly Deck (EVP, CFO). $BNTX $GMAB BGNE SNY CMTX IMNM PRTA PHMMF DCOY Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2090775723531219121?s=20
0 · Reply
AdelinaBinette1049
AdelinaBinette1049 Aug. 21 at 7:21 AM
$ETHA $KEEL $SCHD $EROC $BNTX Ethereum ETF exposure benefits from ETH adoption and institutional flows, KEEL remains speculative, SCHD provides diversified dividend exposure, EROC remains energy-sensitive, and BioNTech remains focused on oncology and vaccine development. I'm watching ETH flows, dividends, energy prices, and clinical milestones.
0 · Reply